Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 nov. 2025 05h09 HE | Source: Research and Markets

Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis (Psoriasis Vulgaris) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.This...
09 mai 2025 06h45 HE | Source: Research and Markets

Stelara (Ustekinumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Stelara (Ustekinumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ...
24 oct. 2024 09h53 HE | Source: Research and Markets

Ustekinumab (Stelara) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ustekinumab (Stelara) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
22 oct. 2024 07h00 HE | Source: Teva Pharmaceutical Industries Ltd

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved...
30 sept. 2024 09h37 HE | Source: Research and Markets

Plaque Psoriasis Drug Forecast and Market Analysis to 2030: Focus on SAR44156, JNJ-2113, sonelokimab, DC-806, orismilast, Piclidenoson, and TAK-279

Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This...
26 sept. 2024 04h17 HE | Source: Research and Markets

U.S. Psoriasis Treatment Awareness & Satisfaction Report: A Review of 2023 - Provides Valuable Insights Into Must-Have Patient-Reported Data Points

Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ...
11 juil. 2024 08h00 HE | Source: Samsung Bioepis

Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report

Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
01 juil. 2024 02h03 HE | Source: Samsung Bioepis

FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara

PYZCHIVA becomes Samsung Bioepis’ seventh biosimilar and fourth immunology biosimilar approved by the FDAPYZCHIVA’s licensing period will begin on February 22, 2025, in the United States, based on the...
09 mai 2024 08h00 HE | Source: Rani Therapeutics, LLC

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
05 févr. 2024 08h00 HE | Source: Rani Therapeutics, LLC

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)

- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111...

Page suivante